Trial Search Results

A Dose-escalation Study of the Safety and Tolerability of Orally Administered TG101348 in Patients With Myelofibrosis

The purpose of this study is to evaluate the safety and tolerability of orally administered TG101348 in patients with myelofibrosis.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

TargeGen

Stanford Investigator(s):

Intervention(s):

  • Drug: TG101348

Phase:

Phase 1

Eligibility


Inclusion Criteria:

   - Diagnosis of myelofibrosis (primary, post-polycythemia vera, or post-essential
   thrombocythemia)

   - At least 18 years of age.

   - ECOG PS 0, 1, or 2.

Exclusion Criteria:

   - Any chemotherapy, immunomodulatory therapy, immunosuppressive therapy,
   corticosteroids, or growth factor treatment within 14 days prior to initiation of
   study drug.

   - Major surgery or radiation therapy within 28 days prior to initiation of study drug.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Andrea Linder
6507254047
Not Recruiting